Loading...
•
Mar 31, 2022
InspireMD Q1 2022 Earnings Report
InspireMD's Q1 2022 financial results were reported, highlighting a revenue increase and progress in commercial strategies.
Key Takeaways
InspireMD reported a 17.6% increase in revenue for Q1 2022, driven by a 19.8% increase in CGuard EPS sales volume. The company's net loss increased due to higher operating expenses related to the C-Guardians FDA study and share-based compensation. The company continues to expand its delivery systems around CGuard and expects to launch innovative delivery solutions in early 2023.
Revenue increased by 17.6% to $1,183,000 compared to Q1 2021.
CGuard EPS sales volume increased by 19.8% to $1,161,000 compared to Q1 2021.
Gross profit increased by $16,000 to $122,000 compared to Q1 2021.
Net loss totaled $4,481,000, or $0.57 per share, compared to a net loss of $3,243,000, or $0.53 per share, for the same period in 2021.
Revenue by Segment
Forward Guidance
InspireMD anticipates launching new delivery solutions such as CGuard Prime and SwitchGuard in early 2023 to facilitate greater utilization of their devices as a first-line solution for carotid artery disease management.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...